Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum beta2-microglobulin levels were measured, by radioimmunoassay, in patients suffering from a variety of benign and malignant clinical disorders. Elevated beta 2-microglobulin values were found in neoplastic and non-neoplastic disorders affecting a variety of organs. The most striking increases in beta 2-microglobulin are found in the plasma cell dyscrazias and several solid tumors, particularly those affecting the lung. Lymphoid neoplasms demonstrate a spectrum of changes of serum beta 2-microglobulin. At the one end of this spectrum were the plasma cell tumors, which show a high incidence of raised beta 2-microglobulin levels, while patients with Hodgkin's disease rarely show such increases in circulating beta 2-microglobulin.
 ...
PMID:beta 2-microglogulin levels in cancerous and other disease states. 5 15

Cerebrospinal fluid (CSF) and serum samples of 20 patients with central nervous system manifestations of hematological malignancies including primary cerebral lymphoma (n = 5) and disseminated non-Hodgkin lymphoma (n = 7) were examined for albumin, IgG, IgM, fibronectin, beta 2-microglobulin, interleukin-6, soluble interleukin-2 receptor, tumor necrosis factor alpha, and oligoclonal immunoglobulin bands. Although a broad range of abnormalities were detected, no reliable CSF parameter for the diagnosis of leptomeningeal spread from hematological neoplasias could be identified. An analysis of 61 repeat lumbar punctures added little to the findings of the first CSF examinations. Currently, immunochemical studies of CSF cell surface markers and early biopsy have probably more clinical value than the determination of the humoral CSF parameters included in this study. However, analysis of cytokine synthesis by single CSF cells using molecular biology techniques may improve the differential diagnosis of hematological neoplasia of the brain and spinal cord in the future.
 ...
PMID:Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. 141 21

This report describes the antigenic profile of the proliferating cells of pulmonary histiocytosis X (HX) in a patient treated with chemotherapy for Hodgkin's lymphoma; the association of pulmonary HX and Hodgkin's disease has rarely been described in the literature. The histopathological diagnosis of HX was confirmed with the aid of monoclonal antibodies (mAbs) to CD4, CD1a, and polyclonal serum anti S-100 protein. The phenotype of HX cells has been analysed using a panel of mAbs against HLA class I A, B, C monomorphic determinants, locus A and B, beta 2-microglobulin, HLA class II distinct monomorphic determinants, DP, DQ, DR, intercellular adhesion molecule-1 (ICAM-1) and vitronectin receptors. Our results indicate that HX cells express HLA class I and II, including locus A, locus B and DP, DQ, DR, like their normal counterpart (represented by Langerhans cells) and detectable levels of ICAM-1 but not vitronectin receptors. We would like to stress the possibility of the association of HX and Hodgkin's lymphoma extending the immunophenotypic profile of HX cells.
 ...
PMID:Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies. 170 28

A review of prognostic factors described recently in Hodgkin's and non-Hodgkin's lymphomas is presented with some comments on their interest and value for treatment choice and comprehension of the disease. The most important parameters are divided into three categories: 1) age; 2) extent of the tumor, ie, number of nodal or extranodal sites, bulkiness, stage, lactate dehydrogenase level or beta 2-microglobulin level; and 3) host-tumor interaction, ie, performance status, serum albumin level, and erythrocyte sedimentation rate. These initial parameters permit the stratification of lymphoma patients into subgroups with different outcomes in which different therapeutic modalities are tested.
 ...
PMID:Prognostic factors in Hodgkin's and non-Hodgkin's lymphomas. 175 78

Serum beta 2-microglobulin concentration was investigated in 221 patients with malignant lymphoma (Hodgkin type and non-Hodgkin type). In 55% of the unselected group of patients increased serum concentrations of beta 2-microglobulin were found. There was a close correlation between tumor extension and beta 2-microglobulin levels. In the tumor stage I the beta 2-microglobulin concentration was 1.65 +/- 0.45 mg/l, in the stage II 2.41 +/- 0.65 mg/l. The levels in the stage III (3.48 +/- 1.15 mg/l) and in the stage IV (5.49 +/- 1.99 mg/l) were significant higher than normal. Using longitudinal studies, measurement of beta 2-microglobulin was followed up during the course of the disease. During tumor regression by an effective antineoplastic therapy initially elevated beta 2-microglobulin concentrations decreased. In patients who achieved a complete remission a normalization of beta 2-microglobulin concentration was seen. We conclude from our findings that beta 2-microglobulin has the characteristics of a tumor associated marker in patients with malignant lymphomas. The low specificity and sensitivity limits the clinical use of this parameter.
 ...
PMID:[Beta 2 microglobulin in serum--a "tumor marker" in malignant lymphomas?]. 217 98

The investigation was conducted to study the role of the determination of tumor markers (CEA, beta 2-microglobulin, IgE and ferritin) in patients with malignant lymphomas. Altogether 66 patients with Hodgkin's disease, 60 with non-Hodgkin's lymphomas and 15 with clinico-hematological remission over one year were investigated, using commercial kits of reagents. An increase in the level of beta 2 was shown to depend on the spreading of a lymphoproliferative process. An elevated level of IgE was noted in Hodgkin's disease whereas a significant rise was unnoticed in non-Hodgkin's lymphomas. An increase in the level of serum ferritin was noted in an advanced and aggressive lymphoproliferative process. The CEA test in malignant lymphomas is not informative.
 ...
PMID:[The importance of the radioimmunological determination of tumor markers in the diagnosis of malignant lymphomas]. 268 5

We have studied the serum beta 2-microglobulin (beta 2m) and thymidine kinase (TK) levels in 19 newly diagnosed lymphoma patients. The proportion of the S-phase cells (SPF) was determined by flow cytometry from subsequently taken tumor biopsy material. A positive correlation between SPF and TK (r = 0.4, P = 0.1), but not between SPF and beta 2m, was seen in the whole material. Sixty-three percent of the high-grade malignancy non-Hodgkin lymphomas (5/8) showed high proliferative activity in both the SPF and TK analyses. Furthermore, high tumor SPF and enhanced serum TK levels reflected equally well and consistently the clinical outcome of the underlying disease.
 ...
PMID:Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas. 305 29

The value of serum deoxythymidine kinase (TK) for the staging and evaluation of disease activity of non-Hodgkin lymphoma (NHL) as compared with serum beta 2-microglobulin, serum lactate dehydrogenase, blood sedimentation rate, blood hemoglobin, white blood cell count, lymphocyte count and platelet count was investigated in 101 patients. In addition, the performance status was determined by the Karnofsky index. Patients with chronic lymphocytic leukemia (CLL; n = 43) and immunocytoma (IC; n = 19) were staged according to the Binet classification, and the other low (n = 28) and high grade NHL (n = 8) according to the Ann Arbor classification. The analysis of all CLL and IC patients revealed that TK values correlated better with Binet stages (p = 0.01; n = 58) than blood sedimentation rate (p = 0.05, n = 12), lactate dehydrogenase (p = 0.08; n = 50), beta 2-microglobulin (p = 0.29; n = 28), lymphocyte count (p = 0.70; n = 57), white blood cell count (p = 0.69, n = 59) and the Karnofsky index (p = 0.16, n = 50). Mean TK levels of these patients were for Binet stage A 6.2 +/- 0.8 U/l (mean +/- S.E.M., range 2.3-18.0), stage B 13.3 +/- 6.5 U/l (3.8-38.8) and stage C 19.6 +/- 4.4 U/l (1.9-79.0), and for 22 healthy controls 3.8 +/- 0.2 U/l (2.2-6.0). Patients with multiple courses of chemotherapy (n = 32) previous to the study had significantly (p = 0.01) higher TK levels (16.4 +/- 3.7 U/l; 2.3-79.0) than those with only up to one course (n = 66; TK: 8.6 +/- 1.4 U/l; 1.5-66.3). The follow-up of 16 patients with low grade NHL showed that serum TK levels paralleled well the clinical response. The results indicate that TK might be a worthful parameter to estimate progression and response to therapy of NHL.
 ...
PMID:Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. 317 80

We have assessed the diagnostic value of the determination of cerebrospinal fluid lactate dehydrogenase, carcinoembryonic antigen, beta 2-microglobulin, beta-glucuronidase and total protein, using linear discriminant analysis, in detecting central nervous system metastases from extracranial malignancies. We conclude that, using these tests, it is impossible to differentiate between control individuals and patients with brain or epidural metastases. Leptomeningeal dissemination from either solid tumours or non-Hodgkin lymphoma could be differentiated from control individuals and patients with brain or epidural metastases. In this differentiation it is essential that bacterial, fungal or tuberculous meningitis be excluded from the differential diagnosis by other diagnostic procedures. The combination of beta-glucuronidase and beta 2-microglobulin provides almost the same diagnostic information as the combination of all parameters.
 ...
PMID:Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. 340 30

Serum beta 2-microglobulin (S-beta 2m) was measured at diagnosis in 189 patients with malignant lymphoma, all with a normal serum creatinine clearance. The diagnosis was non-Hodgkin's lymphoma (NHL) in 149 patients and Hodgkin's disease (HD) in 40. Among the NHL group, S-beta 2m was raised (greater than 3.0 mg/l) in 15% of patients with Stage I and II and in 65% of those with Stage III and IV. The corresponding frequencies for HD were 11% and 83% respectively. In NHL, a high pretreatment level of S-beta 2m was found to be a poor prognostic sign in all stages. Patients in Stage I and II with an elevated pretreatment level of S-beta 2m had a higher relapse rate than those with normal S-beta 2m. In Stage III and IV patients with initial levels greater than 3.5 mg/l, the survival was significantly shorter than in those with initial values of less than 3.5 mg/l. A lower mean S-beta 2m value was found in Stage III and IV patients who achieved complete remission than in those who did not. Serial determinations of S-beta 2m in 23 patients with NHL showed that increased pretreatment levels became normal when remission was achieved and increased again in relapse. Thus the S-beta 2m provides valuable prognostic information in this group of patients.
 ...
PMID:Serum beta 2-microglobulin in malignant lymphoma. 618 72


1 2 Next >>